Evidence map›Paper›PMID 39648869›Full record

ArticleAngewandte Chemie (International ed. in English)2025

The Amplification of Alpha-Synuclein Amyloid Fibrils is Suppressed under Fully Quiescent Conditions.

Azad Farzadfard, Thomas O Mason, Antonin Kunka, Hossein Mohammad-Beigi, Kaare Bjerregaard-Andersen, Jonas Folke, Susana Aznar, Pekka Kallunki, Alexander K Buell

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The amplification of α-synuclein amyloid fibrils.Biochemical Society transactions · 2026
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Azad FarzadfardProtein Biophysics group, Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads, Building 227, 2800, Kgs., Lyngby.ORCID https://orcid.org/0000-0003-1433-2439
Thomas O MasonProtein Biophysics group, Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads, Building 227, 2800, Kgs., Lyngby.ORCID https://orcid.org/0000-0002-4813-8776
Antonin KunkaProtein Biophysics group, Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads, Building 227, 2800, Kgs., Lyngby.ORCID https://orcid.org/0000-0002-1170-165X
Hossein Mohammad-BeigiProtein Biophysics group, Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads, Building 227, 2800, Kgs., Lyngby.ORCID https://orcid.org/0000-0003-2303-795X
Kaare Bjerregaard-AndersenH. Lundbeck A/S, Carl Jacobsens Vej 22, 2500, København, Denmark.ORCID https://orcid.org/0000-0003-3609-3408
Jonas FolkeCentre for Neuroscience and Stereology, Department of Neurology, Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen, Nielsine Nielsen Vej 6B, Entrance 11B, DK-, 2400, Copenhagen NV.ORCID https://orcid.org/0000-0002-0940-3098
Susana AznarCentre for Neuroscience and Stereology, Department of Neurology, Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen, Nielsine Nielsen Vej 6B, Entrance 11B, DK-, 2400, Copenhagen NV.ORCID https://orcid.org/0000-0001-7940-6246
Pekka KallunkiH. Lundbeck A/S, Carl Jacobsens Vej 22, 2500, København, Denmark.ORCID https://orcid.org/0000-0003-1341-7238
Alexander K BuellProtein Biophysics group, Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads, Building 227, 2800, Kgs., Lyngby.ORCID https://orcid.org/0000-0003-1161-3622

Funding

HORIZON EUROPE European Research Council ERC CoG 101088163 EMMAHORIZON EUROPE Marie Sklodowska-Curie Actions 101106115Lundbeck Foundation R366-2021-169Lundbeck Foundation R400-2022-1103Lundbeck Foundation R400-2022-911Michael J. Fox Foundation for Parkinson's Research MJFF-021293Novo Nordisk Foundation NNF17SA0028392Region Hovedstadens Forskningsfond til Sundhedsforskning A7031
6 · The paper itself

Abstract

Seed amplification assays (SAAs) are a promising avenue for the early diagnosis of neurodegenerative diseases. However, when amplifying fibrils from patient-derived samples in multiwell plates, it is currently highly challenging to accurately quantify the aggregates. It is therefore desirable to transfer such assays into a digital format in microemulsion droplets to enable direct quantification of aggregate numbers. To achieve transfer from conventional plate-based to the microfluidic digital format, effective seed amplification needs to be achieved inside the microdroplets. Therefore, we establish a new set of assay conditions that enable highly efficient seed amplification in plates without any shaking. However, the same set of conditions displayed a very different behavior upon transfer to a microfluidic platform where no amplification was observed. We demonstrate that this is caused by the suppression of all secondary processes that could amplify the seeds in the complete absence of mechanical perturbations inside the microdroplets. We further show that the amplification inside droplets can be achieved by subjecting the microemulsions to high-frequency vibrations using a piezo device. Taken together, our results provide novel insights into the physical requirements of alpha-synuclein seed amplification and demonstrate a pathway towards the development of effective digital SAAs.

Indexed as

alpha-SynucleinAmyloidHumansMicrofluidic Analytical Techniquesalpha-SynucleinAmyloidalpha-synucleinAmyloiddiagnosticsdigital seed amplification assaymicrodropletsParkinson's diseasesecondary nucleationsynucleinopathy

Identifiers

PMID39648869
PMCPMC11811685

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.